Skip to content
View in the app

A better way to browse. Learn more.

BariatricPal

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Obesity Treatment News

The latest on bariatric surgery and GLP-1 medicines, written for patients and the clinicians who treat them.

Prior GLP-1 use did not blunt surgical weight loss in a large NYU Epic study

ASMBS-presented Epic Cosmos data show people who took semaglutide or tirzepatide before bypass or sleeve still reached large total losses after the operation.

What happened

NYU Grossman School of Medicine researchers reviewed Epic Cosmos records from 2019 through 2025 for people prescribed a GLP-1 medicine in the six months before metabolic surgery. The medication-exposed group included 2,395 gastric bypass and 4,315 sleeve cases. Comparators without recent GLP-1 use numbered about 40k bypass and roughly 87k sleeve cases without recent medication.

People on semaglutide or tirzepatide lost roughly 8% of body weight in the months before the operation. After surgery, cumulative loss rose above 25% with bypass and about 20% with sleeve. Direct-to-surgery patients were only about 2 to 3 percentage points higher after the procedure, which the authors read as little loss of surgical effect after prior medication.

Restarting medication after surgery was common. In year one, about 44% of prior-GLP-1 bypass patients and 57% of sleeve patients resumed a drug. By year three, roughly two-thirds of the prior-medication group were back on a GLP-1. ASMBS President Richard Peterson, not on the study team, said medicines may open a journey that surgery still finishes for many people with severe obesity.

What it means

Someone already on a GLP-1 who is evaluating an operation can use this as evidence that recent medication exposure, by itself, was not linked to a large drop in one-year surgical weight outcomes in this dataset. Teams may still plan how long to hold a drug around anesthesia and how to handle restart decisions later.

High post-op restart rates also support treating obesity as chronic care rather than a one-and-done choice between a pen and an operation.

What it does not mean

It is not a promise of a specific percentage for any reader. It does not say every patient needs lifelong medication after surgery, or that medication before surgery is required. It is observational electronic-record work, not a randomized trial of sequencing.

Sources

  1. ASMBS primary release, May 5, 2026 prior-medication surgery series

Related guide

Bariatric surgery Information Center hub

Related discussion

GLP-1 Weight Loss Medications forum

Educational information only. Not medical advice. Do not start, stop, or change treatment from this brief.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.